Cargando…
SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans have been exposed to distinct SARS-CoV-2 antigens, either by infection with different variants, and/or vaccination. Population immunity is thus highly heterogeneous, but the impact of such heterogeneity on th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384671/ https://www.ncbi.nlm.nih.gov/pubmed/35920058 http://dx.doi.org/10.1093/infdis/jiac332 |
_version_ | 1784769458823233536 |
---|---|
author | Manali, Maria Bissett, Laura A Amat, Julien A R Logan, Nicola Scott, Sam Hughes, Ellen C Harvey, William T Orton, Richard Thomson, Emma C Gunson, Rory N Viana, Mafalda Willett, Brian Murcia, Pablo R |
author_facet | Manali, Maria Bissett, Laura A Amat, Julien A R Logan, Nicola Scott, Sam Hughes, Ellen C Harvey, William T Orton, Richard Thomson, Emma C Gunson, Rory N Viana, Mafalda Willett, Brian Murcia, Pablo R |
author_sort | Manali, Maria |
collection | PubMed |
description | Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans have been exposed to distinct SARS-CoV-2 antigens, either by infection with different variants, and/or vaccination. Population immunity is thus highly heterogeneous, but the impact of such heterogeneity on the effectiveness and breadth of the antibody-mediated response is unclear. We measured antibody-mediated neutralization responses against SARS-CoV-2(Wuhan), SARS-CoV-2α, SARS-CoV-2δ, and SARS-CoV-2ο pseudoviruses using sera from patients with distinct immunological histories, including naive, vaccinated, infected with SARS-CoV-2(Wuhan), SARS-CoV-2α, or SARS-CoV-2δ, and vaccinated/infected individuals. We show that the breadth and potency of the antibody-mediated response is influenced by the number, the variant, and the nature (infection or vaccination) of exposures, and that individuals with mixed immunity acquired by vaccination and natural exposure exhibit the broadest and most potent responses. Our results suggest that the interplay between host immunity and SARS-CoV-2 evolution will shape the antigenicity and subsequent transmission dynamics of SARS-CoV-2, with important implications for future vaccine design. |
format | Online Article Text |
id | pubmed-9384671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93846712022-08-18 SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity Manali, Maria Bissett, Laura A Amat, Julien A R Logan, Nicola Scott, Sam Hughes, Ellen C Harvey, William T Orton, Richard Thomson, Emma C Gunson, Rory N Viana, Mafalda Willett, Brian Murcia, Pablo R J Infect Dis Major Article Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans have been exposed to distinct SARS-CoV-2 antigens, either by infection with different variants, and/or vaccination. Population immunity is thus highly heterogeneous, but the impact of such heterogeneity on the effectiveness and breadth of the antibody-mediated response is unclear. We measured antibody-mediated neutralization responses against SARS-CoV-2(Wuhan), SARS-CoV-2α, SARS-CoV-2δ, and SARS-CoV-2ο pseudoviruses using sera from patients with distinct immunological histories, including naive, vaccinated, infected with SARS-CoV-2(Wuhan), SARS-CoV-2α, or SARS-CoV-2δ, and vaccinated/infected individuals. We show that the breadth and potency of the antibody-mediated response is influenced by the number, the variant, and the nature (infection or vaccination) of exposures, and that individuals with mixed immunity acquired by vaccination and natural exposure exhibit the broadest and most potent responses. Our results suggest that the interplay between host immunity and SARS-CoV-2 evolution will shape the antigenicity and subsequent transmission dynamics of SARS-CoV-2, with important implications for future vaccine design. Oxford University Press 2022-08-03 /pmc/articles/PMC9384671/ /pubmed/35920058 http://dx.doi.org/10.1093/infdis/jiac332 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Major Article Manali, Maria Bissett, Laura A Amat, Julien A R Logan, Nicola Scott, Sam Hughes, Ellen C Harvey, William T Orton, Richard Thomson, Emma C Gunson, Rory N Viana, Mafalda Willett, Brian Murcia, Pablo R SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title | SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title_full | SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title_fullStr | SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title_full_unstemmed | SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title_short | SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity |
title_sort | sars-cov-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384671/ https://www.ncbi.nlm.nih.gov/pubmed/35920058 http://dx.doi.org/10.1093/infdis/jiac332 |
work_keys_str_mv | AT manalimaria sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT bissettlauraa sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT amatjulienar sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT logannicola sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT scottsam sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT hughesellenc sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT harveywilliamt sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT ortonrichard sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT thomsonemmac sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT gunsonroryn sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT vianamafalda sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT willettbrian sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity AT murciapablor sarscov2evolutionandpatientimmunologicalhistoryshapethebreadthandpotencyofantibodymediatedimmunity |